The response of NSCLC harboring L858R mutation or exon 19 deletion to EGFR-TKIs gefitinib, erlotinib, afatinib, and osimertinib were around 70~80% in multiple clinical trials [7,19,20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.